Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Relmada Therapeutics, Inc. Q3 2026 Earnings Call Summary
Relmada (RLMD) Q3 2026 Earnings Call Transcript
What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call Transcript
Relmada Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate. Cash and Equivalents $202.1M.
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics Q2 Earnings Call Highlights
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.